by jtcir-auto | Aug 6, 2020 | Press Releases
- Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency- Safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence...
by jtcir-auto | Aug 6, 2020 | Press Releases
- Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency- Safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence...
by jtcir-auto | Aug 5, 2020 | Press Releases
CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today the closing of...
by jtcir-auto | Aug 5, 2020 | Press Releases
CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today the closing of...
by jtcir-auto | Aug 3, 2020 | Press Releases
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today that it has...
by jtcir-auto | Aug 3, 2020 | Press Releases
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today that it has...